Shareholders Fight Hemispherx's Fee-Shifting In Del. Chancery
Attorneys for shareholders derivatively suing Hemispherx Biopharma Inc. over bonuses paid to the company's board members asked a Delaware Chancery judge on Monday to invalidate the company's newly enacted fee-shifting bylaw...To view the full article, register now.
Already a subscriber? Click here to view full article